Changing the drug discovery paradigm to anticipate cancer patients’ needs with novel classes of kinase inhibitors.

Learn More


Company Overview

Early stage biotechnology  company developing novel kinase inhibitors for cancer. Inspired by the desire to treat patients we are relentlessly focused on developing the next generation of kinase centric treatments, with better efficacy and selectivity profiles. By focusing on addressing the unmet medical need to provide treatments for patients who develop resistance to existing kinase inhibitors we are uniquely positioned for rapid market entry. Our  founders have extensive Oncology experience in drug discovery, clinical development and commercialization and a passion to bring life extending medicine to patients in need.

Learn More

Our Science

Our proprietary technology, generates unique compounds potently active against protein kinases with a focus on those harboring secondary mutations, for rapid market entry.

Learn More


View Pipeline